Axsome Therapeutics is the better growth buy over Revolution Medicines right now, according to a Motley Fool analysis. Axsome already has three commercialized products—Auvelity, Sunosi, and Symbravo—and recently won two new approvals, driving double-digit revenue gains. Its late-stage pipeline includes five phase 3 programs and a regulatory submission for AXS-12 in narcolepsy. Revolution Medicines, while promising, is earlier-stage with no marketed products, and its stock has surged 135% in the first half, suggesting better buying opportunities may come on a dip. Axsome’s nearer-term growth prospects and room for further stock appreciation make it the preferred choice.
Axsome Therapeutics IncAxsome has three commercialized products and two new approvals driving double-digit revenue gains, with a strong late-stage pipeline.
Revolution Medicines IncRevolution Medicines is earlier-stage with no marketed products, and its stock has surged 135%, suggesting better buying opportunities may come on a dip.